Nordic Life Science 1
TOP STORIES BUSINESS Nikolaj Sørensen, CEO, Orexo
THE COMPANIES WILL DEVELOP AND COMMERCIALIZE AFFIBODY-BASED PET IMAGING TRACERS, WITH AN INITIAL FOCUS ON HER2 AND PD-L1. BUSINE S S D E A L O 14 REXO WILL HAVE the exclusive global commercial rights to the product and intends to launch it in the US in 2022, subject to regulatory approval. “GAIA’s technology and expertise in digital therapeutics are impressive and makes them an ideal partner for Orexo to develop this new treatment. I am convinced that DTx will become an integral and natural part of addiction treatment in the future. This digital therapy for OUD patients is perfectly positioned with Orexo’s competences and commercial organization in the US. GAIAs technology and products can potentially be applied to several other disease areas relevant to Orexo’s current customers and we look forward to continuing our dialogue with GAIA on other possible DTx that can be commercialized by Orexo,” says Nikolaj Sørensen, CEO, Orexo. Under the terms of the agreement, Orexo will be responsible for the clinical development, regulatory approval and commercialization. GAIA will be entitled to royalties, milestone payments and financial compensation during the development phase. Orexo will provide an updated cost guidance for 2019 in connection with the Q3 report release. The increase in the operational expenses for 2019 is expected to be non-material. Future expenses related to OXD-01 will be incorporated into Orexo’s overall cost guidance. “THE COLLABORATION REFLECTS the commitment of Affibody to precision medicine and biomarkerguided patient treatment. It also underlines the competitiveness of our technology and the value of the clinical data that has been generated with Affibody-based imaging agents,” says David Bejker, CEO, Affibody. The Affibody technology is suited for the development of PET imaging tracers and ABY-025, a HER2-detecting Affibody-based PET imaging tracer, is currently in clinical development. ABY-025 provides a novel approach to diagnose global HER2expression in metastatic breast cancer patients using PET imaging. SWEDEN VICORE PHARMA APPROVED FOR LISTING NASDAQ STOCKHOLM’S LISTING COMMITTEE HAS APPROVED VICORE PHARMA HOLDING’S APPLICATION TO BE LISTED ON NASDAQ STOCKHOLM’S MAIN MARKET. “THE UP-LISTING TO Nasdaq Stockholm’s main market is a significant step in our long-term plan to develop Vicore. The aim is to further increase the attractiveness of Vicore shares through increased liquidity as the addressable investor base grows significantly,” says Carl-Johan Dalsgaard, CEO, Vicore Pharma. Carl-Johan Dalsgaard, CEO, Vicore Pharma NORDICLIFESCIENCE.ORG Affibody is currently working together with academic institutions to explore the clinical utility of ABY-025 further. The PD-L1 binding Affibody molecule is being developed as a diagnostic tool to improve selection and monitoring of patients with immunooncology treatments. “We recognize that PET imaging plays a vital role in the development and use of cancer immunotherapies as it is a non-invasive way to measure patient response before, during and after treatment,” says Sanka Thiru, Head of Molecular Imaging Oncology, GE Healthcare. PHOTO JENNY ÖHMAN